Bulgaria vs Serbia: HIV/AIDS deaths averted by antiretroviral therapy
Bulgaria
141.97 deaths
in 2024
Serbia
136.49 deaths
in 2024
Bulgaria rank
118th
Serbia rank
120th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bulgaria
- Serbia
How they compare
Bulgaria currently reports 141.97 deaths against 136.49 deaths in Serbia, a difference of 5.48 deaths.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was Serbia ahead.
Bulgaria ranks 118th and Serbia ranks 120th of 157 countries.
Across the 4 decades both report, Bulgaria averaged higher in 1 and Serbia in 3.
Head to head by decade
| Decade | Bulgaria | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 1.04 deaths | 0 deaths | 1.04 deaths | Bulgaria |
| 2000s | 26.77 deaths | 52.91 deaths | 26.14 deaths | Serbia |
| 2010s | 69.6 deaths | 102.45 deaths | 32.85 deaths | Serbia |
| 2020s | 128.47 deaths | 130.42 deaths | 1.95 deaths | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bulgaria or Serbia?
- Bulgaria, at 141.97 deaths against 136.49 deaths in Serbia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bulgaria and Serbia?
- 5.48 deaths, with Bulgaria ahead.
- How many years of comparable data are there for Bulgaria and Serbia?
- 35 years are reported by both, from 1990 to 2024.
- How do Bulgaria and Serbia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bulgaria ranks 118th and Serbia ranks 120th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.